anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hematologic abnormalities occur with high frequency (up to 70% of patients) in human immunodeficiency virus (HIV) infected individuals. The pathogenesis of these abnormalities is not currently understood, although both an abnormal bone marrow environment (e.g., altered growth factor production) and direct infection and dysfunction of progenitor cells themselves have been postulated. Under the current protocol we have studied bone marrow precursor cells from both HIV infected and uninfected individuals and have shown not only that these cells are infectable in vitro with HIV but also infected in vivo in a subpopulation of seropositive individuals. While the effects of HIV infection of precursor cells on subsequent hematopoietic potential is not completely understood, we could not show a clear correlation between in vivo infection of these cells and suppressed hematopoiesis. It seems clear from this study and others that other alterations within the bone marrow environment must play a role in the clinically observed hematologic abnormalities. We therefore wish to continue our studies to elucidate the relative contributions of direct infection of myeloid progenitor cells and alterations in bone marrow environment in the pathology seen in HIV infected individuals. Understanding the pathogenesis of abnormal hematopoiesis in HIV infection will allow investigators to design appropriate therapeutic strategies. Using recently developed techniques we also wish to use bone marrow cells from HIV infected individuals to establish antibody libraries. This will allow the study of immunologically important epitopes on the HIV virion with potential impact on the subsequent design of HIV vaccines or introduction of passive immunotherapy. Thirdly, research in the field of HIV has been hampered by the lack of an appropriate animal model. One promising approach is the use of human bone marrow to reconstitute lethally irradiated Balb/c mice. Once the human hematopoietic system is established in the mouse, it may be possible to infect these animals with HIV and study in an in vivo model the effects of infection on hematopoiesis.
Pinaverium bromide (PVB) has been shown to protect mice against sepsis, which is predominantly attributed to PVB-mediated anti-inflammatory effects by inhibiting primed neutrophils to produce proinflammatory cytokines. However, the underlying mechanism(s) by which PVB affects neutrophils remains unknown. In this study, we report that treatment with PVB either before or after LPS stimulation attenuated IL-1β and TNF-α expression at both mRNA and protein levels in LPS-activated murine neutrophils. Further experiments revealed that PVB inhibited the phosphorylation of ERK, JNK, and IκBα in LPS-stimulated murine neutrophils. Moreover, PVB reduced reactive oxygen species (ROS) levels via regulating NADPH oxidase 2 (NOX2) activity, as represented by inhibiting p47phox translocation from the cytoplasm to the cellular membrane. Importantly, PVB significantly attenuated IL-1β, TNF-α, IL-6, CXCL1 production in both LPS-stimulated low density neutrophils (LDNs) and normal density neutrophils (NDNs) isolated from septic patients. Collectively, we demonstrated that PVB exerts anti-inflammatory effect by attenuating ROS generation and suppressing the activation of MAPK and NF-κB signaling pathways, suggesting that PVB may act as a potential therapeutic agent for sepsis by inhibiting neutrophil priming and activation.
FIELD: cosmetology. SUBSTANCE: invention deals with glycoproteins rich in hydroxyproline which have average molecular mass 20000 daltons and high solubility in water. Glycoproteins are prepared by acidic-alcoholic extraction from cultures of cells Taxus spp., Gingko biloba, Lycopersicum esculentum and Daucus carota. Glycoproteins of the proposed invention may be used in cosmetic preparative forms instead of animal collagen. EFFECT: improved cosmetologic action. 3 cl, 7 ex
PROBLEM TO BE SOLVED: To improve clarity and middle-wave and long-wave UV absorption by incorporating molybdenum having a specified grain size at the inside of a crystal of a particulate titanium oxide. SOLUTION: The 1-20 wt.% molybdenum or tungsten having 10-150 nm grain size is incorporated at the inside of the crystal of the particulate titanium oxide by precipitating an insoluble hydrous titanium oxide after adding 0.1-20 wt.% modybdate or tungstate based on metal to titanyl sulfate, then hydrolyzing the mixture after adding water, or by precipitating the insoluble hydrous titanium oxide by heating after dissolving urea in a molybdate aq. soln. or a tungstate aq. soln. and cooling, then adding titanium chloride to the aq. soln. at low temp. and aging. The cordex external preparation is obtained by blending 0.1-20 wt.% particulate titanium oxide, a UV absorber or scattering agent, lubricant, alcohols, surfactant, humectant, cell activating agent, whitening agent, antioxidant, preservative, perfume, pigment, etc.  In this way, an aging of the skin and injury due to long-wave UV ray having 290-320 nm wave length is prevented.
The invention discloses diet pills, which consist of the following raw medicinal materials in portions by weight: 20-30 portions of Szechuan lovage rhizome, 20-30 portions of cassia seeds, 20-30 portions of Chinese angelica, 20-30 portions of dried tangerine peel, 10-20 portions of angelica root, 10-20 portions of tuber fleeceflower root, 10-20 portions of liquorice, 5-15 portions of Chinese mugwort leaf, 5-15 portions of wild celery and 5-15 portions of cablin potchouli herb. When in use, the diet pills are orally taken in two to three times every day in terms of 150 g to 200 g every time. In a general way, if the diet pills are taken for about a month, the weight is obviously reduced; furthermore, if the diet pills are taken for about three months, the weight can be essentially reduced up to around standard weight. In the invention, the diet pills have no obvious side effect. People are not anorectic, do not feel like vomiting and having no appetite, etc after taking the diet pills.The diet pills have the advantages of cheap and readily-available raw materials, lower cost, good therapeutic effect and fast response. According to the invention, 33 patients suffered from adiposis are totally cured, the weights of 28 patients are reduced obviously in three months and the effective rate is more than 84 %.
Subjects who have tested positive for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular test from nasal pharyngeal self-swab or a swab administered in a clinical setting at the point of care by a trained clinician. Parallel PCR-based testing occurs in an advanced laboratory to obtain Ct values for positive test results.
The software developed for this research will be downloaded to the phones of the participants in the intervention group. With this software prepared, written and visual information (pictures, mini-videos) will be given to participants every day for 3 months on diabetes, self-management of diabetes and nutrition. Whether the participants read the messages or not will also be monitored through this software. At the end of 3 months, the participants in the intervention and control groups will be invited again, and their biochemical parameters and self-management status will be measured according to the diabetes self-management scale. Data will be collected through face-to-face interviews in the outpatient clinic, and weight will be measured with the bioelectrical impedance analyzer in the outpatient clinic, height will be measured with a height meter fixed to the wall, and waist circumference will be measured with a non-stretchable measuring tape.
The control group (Group 2: Epidural) will receive the 'Blind/standard approach', which is the current standard of care using palpation in administering labor epidural analgesia. Additionally, an anesthesiologist will scan patient's back with Accuro device in turn off mode.
Children will be assessed by two study investigators in two different sessions on the same day, with a washout period of 3 hours between sessions. Intrarater reliability will be determined by comparing rater's scores for each child. These sessions will include goniometric measurements of lower extremity passive range of motion and the 10-Meter Walk Test. Children will have the opportunity to rest or resume normal activities with a minimum of 3 hours between sessions. Interrater reliability will be determined based on the measurements in the same session by 2 different raters.
The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients are given routine rehabilitation treatment.
The invention provides a composition used for relieving exercise-induced fatigue, and a preparation method and an application thereof. The composition comprises the active components of: a maca extract and a puncture weed extract. According to the invention, the maca extract and the puncture weed extract are adopted in combination, such that serum testosterone levels can be greatly improved, and after-exercise fatigue can be relieved or eliminated. With a reasonable ratio of the two components provided by the invention, a synergetic effect is provided, such that the exercise-induced fatigue relieving or eliminating effect is maximized, and athletic ability can be improved. Also, the preparation method is simple, and auxiliary materials are reasonably applied, such that effects of the extracts can be utilized and developed to a maximal extent. The cost is low, and a process satisfies a preparation production specification. The obtained type of preparation is easy to take and easy to be absorbed by human bodies. Generally, the composition, the preparation method and the application are suitable for industrial popularization and application, and have great economic benefits.
Rafaelo's technique consists of delivering a low temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end. The intracellular water in the tissue and the injection of a locally injectable Xylocaine cushion serve as resistance to the vaporisation waves without releasing water vapour, thus avoiding the damage usually encountered in electrosurgery. The delayed phenomenon is cell volatilisation. Vaporisation of the tissue allows significant haemostasis without burns. Tissue changes will depend directly on the temperature emitted and the duration of exposure to the radiofrequence current. The fibrosis process starts during the session and continues for several days to weeks, allowing the reduction of the haemorrhoidal cushions.
Impaired Liver Function 

Do not use EnilloRing in women with liver disease such as acute viral hepatitis or severe (decompensated) cirrhosis of the liver  [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of CHC use until markers of liver function return to normal and CHC causation has been excluded  [see Use in Specific Populations (8.6)]. Discontinue EnilloRing use if jaundice develops. 

Liver Tumors 

EnilloRing is contraindicated in women with benign and malignant liver tumors  [see Contraindications (4)]. Hepatic adenomas are associated with CHC use. An estimate of the attributable risk is 3.3 cases per 100,000 CHC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. 

Studies have shown an increased risk of developing hepatocellular carcinoma in long term (>8 years) CHC users. However, the attributable risk of liver cancers in CHC users is less than one case per million users.
Participants assigned to the control group will likely participate in educational topics related to healthy living for men living with HIV. Procedures in both arms will encompass 3-5 individual sessions lasting 30-60 minutes over 2-3 months. There may also be a booster session at approximately the six-month timepoint.
All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
Participants during the extension phase of the study will receive atezolizumab at a dose of 1200 mg IV on Day 1 in combination with gemcitabine at a dose of 1250 milligrams per square meter (mg/m\^2) on Days 1 and 8 and cisplatin at a dose of 75 mg/m\^2 on Day 1 (four or six 21-day cycles at the discretion of the investigator), followed by atezolizumab as a single agent at a dose of 1200 mg IV q3w on Day 1 of a 21-day cycle) as maintenance treatment continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
Participants will receive a placebo with repeated dosing for 7 days. On day 1 and 6/7 of the 7-day dosing, subjects will complete laboratory sessions.
Investigators will enroll preschoolers with the minimal responder profile who are scheduled to begin the PRT-based public EI program. Consenting parents will be offered a virtual intervention in which they will be randomized to 1 of 2 arms to receive coaching in either (a) PRIMeR intervention, designed to target areas of weakness in the minimal responder profile, or (b) PRT, the treatment model used in the EI program. Coaching will take place on a virtual (video-conferencing) platform. Each child's progress on treatment targets will be assessed in a single case experimental design (SCED) using data from blind-coded video-recordings of parent-child play episodes using a standard set of toys. Overall study effects will be based on aggregated data for an anticipated n of 20 participants assigned to each arm (4 SCED series with 5 participants each contributing to each arm). The primary outcome is gains in children's social initiations (video-coded); the secondary outcome is gains in children's communication levels (multi-method assessment). Mixed methods will be used to evaluate aspects of parents' experiences,
Galectin-3 is a pro-inflammatory molecule functioning as a cytokine hub, and also regulates unfolded protein responses (UPR) and ER stress. Thus, galectin-3 serves as a target for ameliorating inflammatory diseases such as allergic inflammation and diabetic inflammation and insulin resistance. RNA interference of endogenous galectin-3 expression, upregulates IL-12, IL-10 while downregulating IL-23 production, which offers protection against allergic inflammation. In addition, endogenous galectin-3 knockdown causes upregulation of XBP1, alleviating ER stress. Together, upregulated XBP1 and IL-10 offer protection against obesity-induced inflammation. Therefore, the embodiment of the invention resides in RNA interference of endogenous galectin-3 in appropriate cell types in order to rectify allergic and/or diabetic inflammation.
A cyclic aminobenzoic acid derivative and an addition salt thereof which are effective as a human peroxisome proliferator-activated receptor (PPAR) agonist, especially an agonist against a human PPAR iso form, in the treatment of lipid metabolism abnormality, diabetes, etc.; and a medicinal composition containing the derivative or salt. The derivative is a cyclic aminobenzoic acid derivative represented by the general formula (1): [Chemical formula 1] [wherein ring Ar represents optionally substituted aryl, etc.; Y represents C1-4 alkylene, C2-4 alkenylene, C2-4 alkynylene, etc.; Z represents oxygen, sulfur, or -(CH2)n- (n is 0, 1, or 2); X represents hydrogen, halogeno, optionally halogenated lower alkyl, etc.; R represents hydrogen or lower alkyl; and -COOR is bonded in an ortho or meta position to the position where the ring W is bonded]. The salt is a pharmacologically acceptable salt of the derivative.
* Stop Tri-VyLibra if an arterial thrombotic event or venous thromboembolic (VTE) event occurs.
  * Stop Tri-VyLibra if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately [see Adverse Reactions (6.2)].
  * If feasible, stop Tri-VyLibra at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during and following prolonged immobilization.
  * Start Tri-VyLibra no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.
  * The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 cases per 10,000 woman-years. The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued.
  * Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). This risk increases with age, particularly in women over 35 years of age who smoke.
  * Use COCs with caution in women with cardiovascular disease risk factors.
Poor oral health is associated with cardiovascular disease and dementia. Potential pathways include sepsis from oral bacteria, systemic inflammation, and nutritional deficiencies. However, in post-industrialized populations, links between oral health and chronic disease may be confounded because the lower socioeconomic exposome (poor diet, pollution, and low physical activity) often entails insufficient dental care. We assessed tooth loss, caries, and damaged teeth, in relation to cardiovascular and brain aging among the Tsimane, a subsistence population living a relatively traditional forager-horticulturalist lifestyle with poor dental health, but minimal cardiovascular disease and dementia. Dental health was assessed by a physician in 739 participants aged 40-92 years with cardiac and brain health measured by chest computed tomography (CT; n = 728) and brain CT (n = 605). A subset of 356 individuals aged 60+ were also assessed for dementia and mild cognitive impairment (n = 33 impaired). Tooth loss was highly prevalent, with 2.2 teeth lost per decade and a 2-fold greater loss in women. The number of teeth with exposed pulp was associated with higher inflammation, as measured by cytokine levels and white blood cell counts, and lower body mass index. Coronary artery calcium and thoracic aortic calcium were not associated with tooth loss or damaged teeth. However, aortic valve calcification and brain tissue loss were higher in those who had more teeth with exposed pulp. Overall, these results suggest that dental health is associated with indicators of chronic diseases in the absence of typical confounds, even in a population with low cardiovascular and dementia risk factors.
FIELD: medicine. SUBSTANCE: present invention describes compounds of formula (I):   wherein X is hydroxy; R 1  and R 2  are the same or different and are methyl, ethyl or trifluoromethyl; Q is singly bond or Q is (CH 2 ) n , wherein n is 0.1-4, and m is 0 or 1. Compounds have antiinflammatory and immunomodulating activity and are capable of inducing differentiation and inhibition of undesired proliferation of some cells. The present invention also describes preparation process, intermediate compound for preparing compound of formula (I) and pharmaceutical composition having antiproliferating activity and method for suppressing morbid states characterized by pathologic cell differentiation and proliferation such as cancer and psoriasis using compounds of formula (I). EFFECT: improved properties of the pharmaceutical composition and more efficient suppression method. 12 cl, 6 dwg, 20 ex, 1 tbl
BACKGROUND: Sepsis causes inflammation in response to infection, often leading to acute lung injury (ALI). Yazhicao (Commelina communis L., YZC) is widely distributed in the global tropics and has good anti-respiratory inflammatory activity; however, the protection of YZC against septic-ALI has not been established.
PURPOSE: The role of YZC in septic-ALI will be investigated in this study.
METHODS AND RESULTS: In this study, YZC was shown to inhibit excessive inflammation and alleviate septic-ALI. Network pharmacology predicts that Quercetin, Acacetin and Diosmetin have the potential to serve as the pharmacological substance basis of YZC in alleviating septic-ALI. The metabolomics results indicated that YZC could improve the metabolic disorders caused by septic-ALI, which were mostly concerned with energy metabolism and amino acid metabolism, with Trimethylamine (TMA)/Trimethylamine N-oxide (TMAO) being potential small molecule metabolic markers for the clinical diagnosis and treatment of septic-ALI. YZC inhibits the initiation and progression of septic-ALI by controlling the TMA/TMAO metabolites. Our results also suggest that YZC protects the intestinal barrier from damage. Furthermore, our research indicated that YZC reduces TMAO synthesis by inhibiting TMA production through remodeling the intestine microbiota. We investigated the mechanism of YZC-mediated protection against septic-ALI and showed that YZC reduced the expression of proteins associated with NLRP3 inflammatory vesicles in the lung by inhibiting the expression of NF-κB.
CONCLUSION: These results show that YZC inhibits the NF-κB/NLRP3 signaling pathway by regulating metabolic and intestinal flora disorders in septic-ALI mice to reduce TMAO synthesis. This study presents a theoretical groundwork for the advancement of novel medications and clinical use of YZC to enhance septic-ALI and furnishes a theoretical rationale for regulating intestinal microbiota as a therapeutic instrument to treat sepsis and septic-ALI.
PROBLEM TO BE SOLVED: To obtain an external preparation having no adverse effect and capable of preventing cutaneous allergy due to hair dying agent by including a medicine preventing or reducing inflow of calcium ion into a mast cell at the first stage of inflammation. SOLUTION: This medicine contains a calcium ion sequestering agent as an active ingredient. It is preferable that the sequestering agent has a bi- or polyfunctional basic acid group. Phosphate group, sulfate group, carbonate group, etc., can be exemplified as the basic acid group. It is preferable that the medicine contains 0.01-10.0% one or two or more kinds of the sequestering agents. In addition, for example, ethylenediamine tetraacetic acid, diethylenetriamine pentaacetic acid, triamine acetate, etc., or metal salts thereof can be exemplified as the sequestering agent. Thus, the medicine effective in treatment of allergic diseases or reduction of skin sensitizing potential due to an oxidation dyeing agent containing paraphenylendiamin, etc., as a main agent.
Participants received weekly doses of tirzepatide subcutaneously (SC) for 72 weeks, starting at 2.5 milligrams (mg) for 4 weeks. Subsequently, the dose was increased by 2.5 mg every 4 weeks up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.